SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following pivotal international approvals for its ANKTIVA cancer therapy in the EU and Saudi Arabia, complemented by robust revenue growth. The community is buzzing about the drug's global market expansion and potential as a chemotherapy-free cancer treatment, anticipating a substantial short squeeze.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is actively discussed following its recent financial results, which showed solid U.S. same-store sales growth and a 15% dividend increase, alongside reports of prominent hedge funds, including Warren Buffett's Berkshire Hathaway, increasing their positions. The community is debating if its "Hungry for MORE" strategy and market leadership can continue to drive growth amidst a mixed restaurant sector and concerns over valuation.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending due to its significant acquisition of Arcellx for promising CAR T-cell therapy, a strategic move seen by the community as bolstering its oncology pipeline, even as reactions are mixed to recent earnings that beat expectations but offered underwhelming 2026 guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis (NASDAQ:PSNL) Shares Down 4.8% - Should You Sell?

Personalis (NASDAQ:PSNL) Shares Down 4.8% - Here's What Happened...

Personalis (PSNL) to Release Earnings on Thursday

Personalis (NASDAQ:PSNL) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Personalis (NASDAQ:PSNL) Trading Up 6.2% - Time to Buy?

Personalis (NASDAQ:PSNL) Trading 6.2% Higher - Here's Why...

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on...

Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, MarketBeat Ratings...

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday...

Personalis (NASDAQ:PSNL) Price Target Raised to $13.00

BTIG Research boosted their price target on Personalis from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>The company said the decision expands coverage beyond its earlier breast cancer indication.</li><li>NeXT Personal uses whole-genome sequencing and advanced noise-suppression processes to identify tiny amounts of circulating tumor DNA (ctDNA) in a patient’s blood.&nbsp;</li><li>The Medicare decision is backed by data generated through a long-term collaboration with the TRACERx consortium.</li></ul>Personalis, Inc. (PSNL) announced on Tuesday that Medicare will now reimburse its NeXT Personal molecular residual disease (MRD) test for use in monitoring patients with early- to mid-stage non-small cell lung cancer (NSCLC).The company stated the decision expands coverage beyond its earlier breast cancer indication, giving broader access to the assay for Medicare beneficiaries.<h2 class="st-heading-2">Why Lung Cancer Coverage Matters</h2>Under the new determination, Medicare will pay for NeXT Personal when used to track cancer recurrence and residual disease in patients with Stage I through Stage III NSCLC.&nbsp;Lung cancer remains the deadliest cancer in the U.S., with hundreds of thousands of Americans diagnosed each year and a high risk of recurrence following initial treatment.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/PSNL">Personalis’ stock</a> traded over 16% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘normal’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_10_065823_png_e12653533e.webp" alt="PSNL’s Sentiment Meter and Message Volume as of 07:00 a.m. ET on Feb. 10, 2026 | Source: Stocktwits" width="936" height="103"><figcaption>PSNL’s Sentiment Meter and Message Volume as of 07:00 a.m. ET on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">How The NeXt Test Works</h2>NeXT Personal uses whole-genome sequencing and advanced noise-suppression processes to identify tiny amounts of circulating tumor DNA (ctDNA) in a patient’s blood. By tracking up to about 1,800 unique tumor mutations, clinicians can detect signs of residual or returning cancer earlier than with traditional imaging.<blockquote>"For the first time, Medicare beneficiaries battling lung cancer will have access to ultrasensitive MRD testing, providing the deep insights needed to manage their care with greater confidence.”-Chris Hall, President and CEO, Personalis</blockquote>The Medicare decision is supported by data from a long-term collaboration with the TRACERx consortium, which recently published results in Cell, validating the test’s performance in lung cancer surveillance.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-rally-hedge-fund-mark-spitznagel-trouble-ahead/cZbUPMiR4Yk">AI Is Real, But The Rally May Not Be: Hedge Fund Veteran Mark Spitznagel Reportedly Sees Trouble Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Division of Pulmonology and Critical Care nurse practitioner Jeanne Millett, left, and pulmonologist Dr. Thomas Smith review lung cancer screening scans.

Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with early to mid-stage non-small cell lung cancer (NSCLC).

Equity

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with early to mid-stage non-small cell lung cancer (NSCLC).


Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL

Wellington Shields Capital Management LLC trimmed its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 31.5% during the 3rd quarter, according to the company in its most recent 13F...

Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold

Wall Street Zen upgraded shares of Personalis from a "sell" rating to a "hold" rating in a research note on Saturday...

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Tech stocks

Energy

Cash / Bonds

Crypto

What&#39;s your biggest portfolio allocation right now?

Stocktwits

What's your biggest portfolio allocation right now?

Stocktwits Polls

The unsuccessful NHS Galleri trial for early cancer detection highlights this company's differentiated focus on targeted MRD and personalized vaccines.

Discussion centers on the company's strong foundation in personalized cancer vaccines and targeted ctDNA tests for recurrence monitoring.

PSNL
Personalis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PSNL News

PSNLPersonalis Inc